OncoMatch/Clinical Trials/NCT06880029

Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy

Is NCT06880029 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies non-drug interventions for triple negative breast cancer (tnbc).

Phase 1/2RecruitingCentro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.NCT06880029Data as of May 2026

CIRCADIAN is a prospective randomized clinical trial designed to evaluate the impact of pembrolizumab infusions' time-of-day on pathological complete response (pCR) rate among TNBC patients undergoing neoadjuvant treatment.

Check if I qualify

Extracted eligibility criteria

Cancer type

Triple-Negative Breast Cancer

Breast Carcinoma

Disease stage

Required: Stage II, III

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify